239 related articles for article (PubMed ID: 21285988)
21. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.
Scheffer SR; Nave H; Korangy F; Schlote K; Pabst R; Jaffee EM; Manns MP; Greten TF
Int J Cancer; 2003 Jan; 103(2):205-11. PubMed ID: 12455034
[TBL] [Abstract][Full Text] [Related]
22. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
Cardillo TM; Trisal P; Arrojo R; Goldenberg DM; Chang CH
BMC Cancer; 2013 Apr; 13():170. PubMed ID: 23548153
[TBL] [Abstract][Full Text] [Related]
23. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
24. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
25. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
[TBL] [Abstract][Full Text] [Related]
27. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
28. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
29. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.
Diken M; Kreiter S; Vascotto F; Selmi A; Attig S; Diekmann J; Huber C; Türeci Ö; Sahin U
Cancer Immunol Res; 2013 Dec; 1(6):386-92. PubMed ID: 24778131
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
31. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
32. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
33. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
Chen Z; Yang H; Li Z; Xia Q; Nie Y
Biochem Biophys Res Commun; 2019 Aug; 516(3):726-732. PubMed ID: 31253398
[TBL] [Abstract][Full Text] [Related]
34. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
35. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
36. Clinical development of mTor inhibitors for renal cancer.
Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
[TBL] [Abstract][Full Text] [Related]
38. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
39. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
